Search our team at AdventHealth Research Institute
-
NCT06072781
VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05154487
GOG 3069 Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if the combination of the drugs alpelisib and fulvestrant is better or worse than the usual approach for your type of cancer. The usual approach is defined as...
-
NCT05891171
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is currently enrolling.Research Area: Cancer ResearchObjectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
-
NCT05919511
MA-GVHD-401: A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaDescribe the clinical course and burden of cGVHD after alloSCT. Describe personal and healthcare resource utilization associated with the management of
cGVHD. Describe practice patterns and therapy... -
NCT06040099
D933GC00002: A Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere™) in Unresectable Hepatocellular Carcinoma
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaAstraZeneca is doing this study to learn more about durvalumab and bevacizumab given together after the TARE Y90 procedure in participants with HCC, and also to better understand HCC and associated...
-
NCT05128825
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of Zn-C3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this Study includes the following: To test the safety of the Study drug and how you will feel while taking the Study drug. To find out what effects, good and/or bad, it has on you and...
-
NCT06064877
AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
This study is currently enrolling.Associated Conditions: ThoracicResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to investigate the safety, effectiveness, and tolerability (whether side effects can be handled by a participant) of ficlatuzumab at two different doses when given...
-
NCT06143891
A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD)) (ROCKnrol-1)
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaDemonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in event free survival.
-
NCT06305767
A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
This study is currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaTo compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed... -
NCT05520099
Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, Florida -
NCT05592626
CP-START-001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)
This study is currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is
To test the safety of study drug STAR0602. To see how well different doses of the study drug STAR0602 are tolerated in different groups of patients. To understand... -
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect...